Robert W. Baird Trims Immutep (NASDAQ:IMMP) Target Price to $6.00
Immutep (NASDAQ:IMMP – Free Report) had its price target trimmed by Robert W. Baird from $7.00 to $6.00 in a report issued on Thursday, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. Separately, Capital One Financial initiated coverage on Immutep in a research note on Friday, May 17th. They […]
More Stories
BRP Inc. (TSE:DOO) Given Consensus Rating of “Hold” by Brokerages
Shares of BRP Inc. (TSE:DOO – Get Free Report) have received a consensus rating of “Hold” from the twelve brokerages...
Critical Comparison: Solaris Energy Infrastructure (NASDAQ:SEI) versus Drilling Tools International (NASDAQ:DTI)
Drilling Tools International (NASDAQ:DTI – Get Free Report) and Solaris Energy Infrastructure (NASDAQ:SEI – Get Free Report) are both small-cap...
The Role of Analytics in Online Radio Station Software
In today’s technology-driven era, where the digital landscape transforms how people interact with media content, radio stations have become a...
EOR or In-House HR to Handle Global Employment?
Venturing into global markets is an exciting yet challenging prospect for many businesses. Strategic HR decisions can help hugely influence...
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine...
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Analysts
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have earned an average rating of “Buy” from the thirteen...